Citations

Clear

2228 citation(s) found for "Le, Anne".

Long-Term Survey to Assess Recurrence and Complications of Surgically Treated Pleomorphic Adenoma
Rourk, Katelyn S. , Hidalgo, C. , Shurtz, Anne K., Tasche, Kendall K. , Price, Daniel L., Abel, Kathryn M. Van , Moore, Eric J., Hidalgo, Cecelia M, Van Abel, Kathryn M , Yin, Linda X , Rourk, Katelyn , Price, Daniel L. , Yin, Linda X. , Moore, Eric J.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | May 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00034894261453714 | PMID 42152554 Get It

Objective(s): To (1) report on the long-term recurrence rate of surgically managed pleomorphic adenoma (PA) and (2) assess long-term surgical outcomes after parotidectomy Methods: Cross-sectional survey of all patients with a pathologic diagnosis of PA who underwent surgical management in a tertiary care center from 01/1997 to 12/2023 and had access to an electronic patient portal. Surveys were delivered via electronic patient portal or phone call with 6 questions to assess recurrence and long-term surgical outcomes. Time to first recurrence and recurrence free survival were analyzed using a Kaplan-Meier curve. Results: Seven hundred-forty-five patients met inclusion criteria and received the survey, with a 56% response rate (n = 420). The clinical median follow-up length was 51 days, which extended to a median length of 6.2 years following the survey. The median change in follow-up length was 5.37 years ( P < .001). The recurrence rate was 1% at 5 years, with a median time to first recurrence of 7.54 years. 13% and 9% of responders reported facial asymmetry and incisional cosmetic concerns, respectively. 33% of patients reported experiencing Frey syndrome, which increased from 5.2% of survey responders with documented Frey syndrome at their original post-operative assessment. Conclusion: Long-term assessment of PA outcomes confirms low recurrence rates, suggesting regular surveillance of recurrence is likely unnecessary. Complaints of Frey syndrome increased in frequency with longer term follow-up, which should be considered during patient counseling. Level of Evidence: 3
When Does Acceptable Become Unacceptable? Toxicities of Emerging Therapies
Barned, Sydney, Heinzerling, Lucie, Dalvin, Lauren A., Heinzerling, Lucie , Dalvin, Lauren A.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 15, 2026 | Volume: 46 | Issue: 3 | Pages: No page available

10.1200/edbk-26-520698 | PMID 42139644 Get It

Novel systemic anticancer therapies, including immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs), bispecific antibodies, and next-generation targeted agents, have improved survival, expanded into earlier disease settings, and created a growing population of long-term survivors. However, these therapies introduce toxicity profiles that differ substantially from those of traditional cytotoxic chemotherapy, including differences in organs affected, timing of onset, management strategies, and long-term sequelae. Tailored approaches to monitoring, diagnosis, and treatment are therefore required, along with stronger evidence to guide strategies that reduce morbidity and mortality while maintaining antitumor efficacy. Importantly, patients' lived experiences of toxicity often do not align with clinician-graded Common Terminology Criteria for Adverse Events classifications. Nonobservable symptoms, daily functioning, and quality of life must also be taken into account. Here, ocular and cutaneous adverse events are used as illustrative examples of how toxicities that may appear mild can become unacceptable when they impair function, quality of life, or treatment sustainability. Interdisciplinary collaboration between oncologists and organ specialists is essential for optimal recognition and management. At the same time, the evidence base for toxicity risk and management must continue to evolve through registries such as Side Effect Registry Immuno-Oncology and prospective comparative studies. Better tailored treatment strategies, particularly for immune-related adverse events, are needed to preserve both tumor response and organ function while reducing reliance on corticosteroids and broad immunosuppression. Although these therapies are highly effective, their risks must be better understood and managed to maximize patient benefit.
Inhibition of BDNF/TrkB.FL Signaling Reduces Mitochondrial Biogenesis in Rat Cervical Ventral Horn
Davis, Anne, Fogarty, Matthew, Hernandez-Vizcarrondo, Genesis, Davis, Jamiah, Mantilla, Carlos, Sieck, Gary, Dasgupta, Debanjali , Fogarty, Matthew, Mantilla, Carlos B. , Sieck, Gary C.

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2299301 Get It

Brain derived neurotrophic factor (BDNF) signals through its high-affinity full-length tropomyosin receptor kinase-B (TrkB.FL) and plays role in maintaining the survival and function of phrenic motor neurons (PhMNs), neuromuscular transmission and synaptic activity. Disruption of this pathway is a hallmark of several neurodegenerative diseases associated with dysfunction and death of PhMNs with impaired mitochondrial function. BDNF/TrkB.FL signaling phosphorylates CREB at serine 133 (pCREBS133) and promotes its nuclear localization in cervical ventral horn of rats, however its downstream molecular pathway has not yet been established. Recently, we demonstrated that in human airway smooth muscle cells, pCREBS133, as a transcription factor, binds to the CRE sequence in the PGC1a promoter and activates its expression. PGC1a co-transcriptionally activates mitochondrial transcription factor A (TFAM) expression promoting mitochondrial DNA (mtDNA) replication and mitochondrial biogenesis. In the present study, we hypothesized that BDNF/TrkB.FL signaling promotes pCREBS133 phosphorylation and transcriptional activation of PGC1a and downstream expression of TFAM, leading to mitochondrial biogenesis. In this study, we employed a loss of function approach using a novel chemogenetic rat model (TrkBF616A) with a knock-in allele sensitive to the selective kinase inhibitor 1NMPP1 to inhibit TrkB.FL kinase activity. One group of female and male rats were treated intrathecally at C4 with either artificial cerebrospinal fluid (aCSF) or BDNF (450 ng/ 300 g b.w.; diluted in aCSF) for 40 mins, followed by collection of C3-C6 cervical ventral horn. In a second group, female and male rats were treated with 1NMPP1 (25 uM; i.p.) or the vehicle DMSO for 2 h. After 2 h, both groups were treated intrathecally with BDNF for 40 min and the C3-C6 cervical ventral horn collected. Intrathecal BDNF increased the pTrkB.FLY817 autophosphorylation and downstream phosphorylation of pCREBS133. Bioinformatic analysis identified a putative binding site of pCREBS133 on PGC1a promoter, which was confirmed by Chromatin immunoprecipitation (ChIP) assay. Consistent with this, BDNF treatment increased the expression of PGC1a and downstream TFAM, with an increase in mtDNA copy number. 1NMPP1 inhibition of TrkB.FL kinase (blunted BDNF-induced pTrkB.FLY817 phosphorylation) inhibited downstream activation of the pCREBS133/PGC1a/TFAM signaling cascade. Additionally, 1NMPP1 treatment blunted the BDNF-induced increase in mtDNA copy number. We conclude that BDNF/TrKB.FL signaling mediates mitochondrial biogenesis in the cervical ventral horn suggesting that interventions targeting this pathway could be a therapeutic strategy for neurodegenerative diseases. This research was funded by NIH Grants HL146114 & AG44615. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program
O'Hagan, Anne, Loriot, Y, Deprince, Kris, Crow, Lauren, Laron, Michal, Adelman, Ron, Sweiti, Hussein , Triantos, Spyros, Triantos, Spyros , O’Hagan, Anne, Siefker-Radtke, Arlene Odelia , Loriot, Yohann , Laron, Michal

Mayo Clinic

The Oncologist | May 12, 2026 | Volume: 31 | Issue: 7 | Pages: No page available

10.1093/oncolo/oyag174 | PMID 42127981 Get It

Abstract Background Fibroblast growth factor receptors inhibitors (FGFRi) are approved treatments for various malignancies. FGFRi-associated retinopathy is a class effect of FGFRi, including erdafitinib, pemigatinib, infigratinib, and rogaratinib. Patients and Methods We summarized FGFRi-associated retinopathy with erdafitinib across 5 clinical studies in patients with metastatic urothelial cancer (mUC pooled studies) and one study in patients with advanced solid tumors (RAGNAR). We also present changes in visual acuity, retinal pigment epithelial elevation, and subretinal fluid in RAGNAR. Results One hundred and three (21.5%) of 479 patients in the mUC pooled studies and 43/314 (13.7%) patients in RAGNAR experienced FGFRi-associated retinopathy. Most FGFRi-associated retinopathy were Grade 1/2 events. Grade 3 FGFRi-associated retinopathy were infrequent (mUC pooled studies, 11/479 [2.3%]; RAGNAR, 3/314 [1.0%]). No Grade 4 events occurred. Most FGFRi-associated retinopathy events (mUC pooled studies, 81/103 [78.6%]; RAGNAR, 30/43 [70.0%]) occurred within 90 days of treatment initiation and were managed with erdafitinib dose interruption (mUC pooled studies, 41/479 [8.6%]; RAGNAR, 23/314 [7.3%]) or reduction (mUC pooled studies, 58/479 [12.1%]; RAGNAR, 21/314 [6.7%]); few required treatment discontinuation (mUC pooled studies, 14/479 [2.9%]; RAGNAR, 3/314 [1.0%]). By the data cutoff, 63.1% (65/103) patients in the mUC pooled studies and 65.1% (28/43) patients in RAGNAR had their FGFRi-associated retinopathy events resolve. Most unresolved FGFRi-associated retinopathy events were persistent Grade 1 events. In RAGNAR, 92.0% of patients had their visual acuity return to baseline and 78.5% of patients had their retinal pigment epithelial elevation resolve. Conclusions FGFRi-associated retinopathy with erdafitinib can be managed with dose reductions, interruptions, or discontinuations. Proactive collaboration between oncologists and ophthalmologists is required to ensure that erdafitinib delivers clinical benefit to patients while managing their potential adverse symptoms of FGFRi-associated retinopathy.
Macrophage metabolism directs regenerative versus fibrotic healing through BMP signaling in the mouse digit tip
Liu, Siqi, Ramesh, Madhumidha, Raymond, Charlotte, Carleton, John, Tower, Robert , Tower, Robert J , Simkin, Jennifer , Sammarco, Mimi C. , Su, Ni , Carleton, John, Le, Anne , Trostle, Alexander J. , Simkin, Jennifer

Mayo Clinic

No container title available | May 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.04.722661 | PMID 42146602 Get It

ABSTRACT Macrophages play a central role in determining the outcomes of healing, coordinating regeneration in some injuries and scar formation in others. In both cases, this coordination involves the cross-talk between macrophages and surrounding cells. But what drives the different cross-communication pathways to determine healing outcomes is not well known. In this study, we make use of the mouse digit tip amputation model, in which an amputation through the third phalangeal element (P3) is able to completely regenerate whereas an amputation through the second phalangeal element (P2) forms a scar. We identify a population of macrophages that is specific to the P3 regenerating digit. By integrating single-cell RNAseq, spatial transcriptomics, and metabolomic analyses, we show that this population localizes specifically to the growing bone front, express BMP ligands that drive downstream BMP activation in neighboring osteoblasts and is governed by a two-part metabolic switch involving increased fatty acid oxidation coupled with reduced glycolytic activity. This spatially restricted, BMP-expressing macrophage population is entirely absent in the scar-forming P2 injury, and our data indicate that environmental conditions unique to the regenerating digit are responsible for its emergence. Together these findings identify a regeneration-specific macrophage signaling center for patterned bone formation and suggest that targeting the metabolic conditions that drive this population could improve the efficacy of regenerative therapies.
Flow-gradient Phenotypes and Functional Recovery After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis: A COMPARE-TAVI 1 Sub-study
Ravn, Emil Johannes , Vase, Henrik, Nissen, Henrik , Hejlesen, Kristian, Andersen, Karen Juel, Carter‐Storch, Rasmus , Dybro, Anne M., Thim, Troels , Freeman, Phillip , Uttenthal, Frederik , Christensen, Ulrik, Christiansen, Evald H., Terkelsen, Christian Juhl, Dahl, Jordi Sanchez, Carter-Storch, Rasmus , Ravn, Emil Johannes , Vase, Henrik, Mortensen, Nils Sofus Borg , Dybro, Anne M. , Freeman, Phillip Michael , Uttenthal, Frederik , Christiansen, Evald Høj , Terkelsen, Christian Juhl , Dahl, Jordi S.

Mayo Clinic

No container title available | May 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.04.26352421 Get It

BACKGROUND Patients with severe aortic stenosis (AS) exhibit heterogeneous flow-gradient hemodynamics and ventricular remodeling, which may influence symptomatic, functional, and structural responses to transcatheter aortic valve implantation (TAVI). Thus, we evaluated differences in functional recovery and reverse remodeling after transfemoral TAVI across flow-gradient phenotypes. METHODS In this sub-study of the COMPARE-TAVI 1 trial, 975 patients undergoing transfemoral TAVI were classified as classical low-flow low-gradient (cLFLG, 9.1%), paradoxical low-flow low-gradient (pLFLG, 7.7%), low-flow high-gradient (24.7%), normal-flow low-gradient (NFLG, 13.0%), and normal-flow high-gradient (45.4%). The primary functional outcome was longitudinal change in six-minute walk test distance (6MWTD) from baseline to 1 year follow-up. Secondary endpoints included changes in NYHA functional class and reverse remodeling from baseline to 1 year follow-up along with the incidence and risk of all-cause death and a composite MACE-endpoint. RESULTS Mean 6MWTD increased by 59±4 meters at 1-month (p=0.000) with no additional improvement at 1-year, but with heterogeneity between groups (p=0.000). Improvements among NFLG, cLFLG and low-flow high-gradient AS were comparable with normal-flow high-gradient AS, while pLFLG AS exhibited significantly increments at 1-year (−28±15 meters, p=0.007). Patients with NFLG, cLFLG and pLFLG were more symptomatic at baseline (NYHA ≥III: 40.5%, 57.3% and 50.6%, respectively, p=0.000). NYHA improved in all groups at 1-year follow-up (p=0.000), although persistent symptoms at 1-year were most frequent in pLFLG (NYHA ≥II; 38.7%, p=0.012). Reverse remodeling was also comparable between normal-flow high-gradient AS and NFLG, cLFLG, and low-flow high-gradient AS, respectively, but attenuated in pLFLG AS in both unadjusted and adjusted analyses. No differences were observed in the incidence and risk of all-cause death or the composite MACE-endpoint. CONCLUSION TAVI associates with functional recovery across all flow-gradient phenotypes, although with heterogeneous responses. Patients with NFLG showed comparable functional recovery and reverse remodeling at 1-year follow-up compared with normal-flow high-gradient AS, whereas pLFLG demonstrated attenuated benefits across all parameters.
Comparative Precision of 3D MRE and 2D MRE for Measurement of Liver Stiffness in Adults with Severe Obesity
Müller, L, Ceriani, Lael , Harris, David T. , Wolfson, Tanya, Batakis, Danielle, Agni, Rashmi, Covarrubias, Yesenia, Pepin, Kay, Ehman, Richard L. , Heilman, Jeremiah, Panagiotopoulos, Nikolaos, Middleton, Michael S. , Martins, Vitor F. , Gamst, Anthony, Sappenfield, Ryan, Grunvald, Eduardo , Jacobsen, Garth R., Lidor, Anne O. , Goodman, James A. , Khoury, Sami B. , Müller, Lukas , Hamilton, Gavin , Martins, Vitor F , Sappenfield, Ryan , Grunvald, Eduardo , Funk, Luke M , Goodman, James A , Khoury, Sami B , Sirlin, Claude B. , Reeder, Scott B. , Ehman, Richard , Harris, David T. , Wolfson, Tanya, Batakis, Danielle, Agni, Rashmi , Heilman, Jeremiah A., Panagiotopoulos, Nikolaos , Goodman, James A , Sirlin, Claude B.

Mayo Clinic

Radiology | May 5, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.253243 | PMID 42084509 Get It

Compared with two-dimensional MR elastography (MRE), three-dimensional MRE demonstrated better test-retest repeatability, between–field-strength reproducibility, and between-day reproducibility at 3 T for measurement of liver stiffness in adults with severe obesity but failed more frequently.
Effects of Radiotherapy, Immune Checkpoint Inhibitors, and PIM Kinase Inhibition in Castration-Resistant Prostate Cancer
Chennupati, Vignesh , Eximond, Matthew , Nwiloh, Anita, Rajkumar-Calkins, Anne , Wang, Jian, Kirschner, Austin N. , Rajkumar-Calkins, Anne

Mayo Clinic

Current Cancer Drug Targets | May 5, 2026 | Volume: 26 | Issue: No issue available | Pages: No page available

10.2174/0115680096447552260409104759 | PMID 42083536 Get It

Introduction/Objective: Immune checkpoint inhibitors (ICIs) have limited efficacy in prostate cancer. Radiation therapy (RT) combined with ICIs and PI3K inhibition may enhance anti-tumor immune activity. Methods: RT-induced cytosolic double-stranded DNA (dsDNA) was measured in human and mouse prostate cancer cell lines as the surrogate upstream marker consistent with cGAS–STING engagement. In a syngeneic mouse model for castration-resistant prostate cancer (Myc-CaP in FVB mice), triple therapies were studied: (1) anti-CTLA-4, anti-PD-1, and RT, and (2) PIM kinase inhibitor PIM447, anti-PD-1, and RT. Mass cytometry (CyTOF) was used to measure the tumor-immune profile. Results: The peak induction of cytosolic dsDNA was at an RT dose of 13 Gy. In the mouse model, triple therapy with anti-CTLA-4, anti-PD-1, and RT doubled the median survival compared to monotherapy (32 days vs 11 to 22 days, p<0.006). Triple therapy with the PIM kinase inhibitor PIM447, anti-PD-1, and RT nearly tripled the median survival compared to PIM447 monotherapy (82 days vs 29 days, p=0.002). Mass cytometry analysis revealed that the combination of anti-PD-1 and RT reduced myeloid-derived suppressor cells and tissue-associated macrophages and enhanced CD8+ T-cell infiltration. Discussion: Although prostate cancer is an immunocold entity, RT can trigger immune activation, consistent with engagement of the cGAS–STING signaling pathway (cytosolic dsDNA serving as a surrogate upstream marker). In triple therapy, RT can enhance the efficacy of ICI and PI3K-targeted drug therapy, significantly improving overall survival in a mouse model of CRPC. Conclusions: A combination of RT, ICIs, and PIM kinase inhibition may help overcome immune resistance in prostate cancer. This combination therapy approach supports further preclinical validation and careful clinical evaluation and warrants further clinical investigation to optimize treatment strategies for CRPC.
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers
Benveniste, Pierre‐Louis , Létourneau‐Guillon, Laurent , Araújo, David , Fetco, Dumitru , Hori, Masaaki , Kamiya, Kouhei , Messina, Steven, Audoin, Bertrand , Blezek, Daniel, Brisset, Jean‐Christophe , Charlson, Erik, Chen, Michelle , Demortière, Sarah , Edan, Gilles , Filippi, M, Kerbrat, Anne , Kirschke, J, Labauge, Pierre, Liu, Yaou, Mainero, Caterina , Medina, Nilser Laines , Reich, Daniel S. , Shepherd, Timothy M. , Smith, Seth A. , Talbott, Jason, Tauhid, Shahamat , Treaba, Constantina A. , Cohen-Adad, Julien, Fetco, Dumitru , Hori, Masaaki , Audoin, Bertrand , Bakshi, Rohit , Bannier, Elise , Blezek, Daniel , Brisset, Jean-Christophe , Callot, Virginie , Chen, Michelle , Ciccarelli, Olga , Edan, Gilles , Filippi, Massimo , Granberg, Tobias , Granziera, Cristina , Hemond, Christopher C , Keegan, B Mark , Kerbrat, Anne , Kirschke, Jan , Kollind, Shannon H , Lee, Lisa Eunyoung , McGinnis, Julian , Laines Medina, Nilser , Mühlau, Mark , Nair, Govind , O'Grady, Kristin P , Oh, Jiwon , Ouellette, Russell , Reich, Daniel S , Rocca, Maria A , Smith, Seth A , Stawiarz, Leszek , Tam, Roger , Traboulsee, Anthony , Treaba, Constantina Andrada , Valsasina, Paola , Yiannakas, Marios , Cohen-Adad, Julien , Guillon, Laurent Letourneau , Chougar, Lydia , Messina, Steven A. , Tsagkas, Charidimos , Blezek, Daniel J. , Ciccarelli, Olga , Filippi, Massimo , Keegan, B. Mark , Labauge, Pierre , Lee, Lisa Eunyoung , Nair, Govind , O’Grady, Kristin P. , Prat, Alexandre , Rocca, Maria A. , Talbott, Jason F. , Tam, Roger , Lombaert, Hervé

Mayo Clinic

Multiple Sclerosis Journal | April 24, 2026 | Volume: 32 | Issue: 6 | Pages: 598-613

10.1177/13524585261427333 | PMID 42028790 Get It

Background/Objectives: Characterizing spinal cord multiple sclerosis (MS) lesions in MRI is critical for diagnosis, monitoring, and treatment evaluation. However, current automated approaches for lesion detection and segmentation are typically designed for specific MRI contrasts or acquisition sites, limiting their generalizability in real-world clinical settings where imaging protocols vary widely. This work proposes a robust multi-site, multi-contrast segmentation framework for spinal cord lesions. Methods: The segmentation model was trained and evaluated on a large-scale dataset comprising 4428 annotated images from 1849 persons with MS across 23 imaging centers, encompassing six MRI contrasts (T1w, T2w, T2*w, PSIR, STIR, and UNIT1) acquired at 1.5 tesla (T), 3 T, and 7 T. Results: Likert-type assessment performed by neuroradiologist ratings demonstrated superior generalization of the model compared to existing contrast-specific pipelines ( p < 0.01). Additional experiments evaluated robustness across spinal levels, acquisition resolutions, binarization thresholds, and quantitative evaluation on external labeled datasets. Conclusions: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher. Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast
Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup
Grill, Joshua D., Salloway, Stephen, Atri, Alireza, Cogswell, Petrice M., Benzinger, Tammie L. S., Iwatsubo, Takeshi, Greenberg, Steven M., Carrillo, Maria C., Jack, Clifford R., Sperling, Reisa A., Carrillo, María C. , Etten, Ellis S. van , Mahinrad, Simin , Grill, Joshua D. , Salloway, Stephen , Atri, Alireza , Cogswell, Petrice M. , Benzinger, Tammie L.S. , Iwatsubo, Takeshi , Iadecola, Costantino , Lemere, Cynthia Ann , Nicoll, James A. R. , Greenberg, Steven M. , Jack, Clifford R. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | April 22, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71361 | PMID 42015334 Get It

Abstract In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid‐related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials. Since then, anti‐amyloid immunotherapies have received regulatory approval for AD treatment and are beginning to enter clinical practice, underscoring the importance of informing healthcare providers, researchers, and patients about ARIA's implications in real‐world settings. In response, the Alzheimer's Association convened a new workgroup to review current knowledge of ARIA, including underlying mechanisms, clinical presentations, associated risk factors, mitigation strategies, radiologic detection methods, patients’ perspectives in treatment decision‐making, and outstanding challenges. Here, we outline key insights from this workgroup, highlighting that effective ARIA detection and monitoring in clinical practice requires adherence to robust protocols to mitigate risks and enhance patient safety. Limited availability of clinical and pathologic data on predictors of symptomatic and severe ARIA underscores the importance of continued real‐world data collection.